Eton Pharmaceuticals, Inc. (ETON)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 22 | 21 | 32 | 39 | 80 | 106 | 150 |
| Operating profit | $m | 0 | 16 | ||||||
| Net profit | $m | -28 | -2 | -9 | -1 | -4 | -5 | 13 | 29 |
| EPS reported | $ | -0.17 | 0.38 | ||||||
| Operating cashflow per share | $ | 0.39 | 0.55 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | 0.38 | 0.53 | ||||||
| Free cash flow | $m | 10 | 15 | ||||||
| Net debt | $m | 5 | 1 | ||||||
| Book value equity | $m | 26 | 47 | ||||||
| Book value per share | $ | 0.97 | 1.42 | ||||||
| Number of shares | m | 26.91 | 32.79 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 149.97 | ||||||
| P/B LTM | x | 17.40 | 9.77 | ||||||
| P/S LTM | x | 5.69 | 4.31 | ||||||
| P/FCF LTM | x | 44.65 | 30.89 | ||||||
| EV/EBITDA LTM | x | 107.83 | 24.78 | ||||||
| EV/Sales LTM | x | 5.75 | 15.11 | ||||||
| Earnings Yield LTM | % | -1.01% | +0.67% | ||||||
| FCF Yield | % | +2.24% | +3.24% | ||||||
| Quality | |||||||||
| ROE | % | -17.59% | +40.13% | ||||||
| ROIC | % | +0.12% | +20.41% | ||||||
| Operating margin | % | +0.09% | +15.44% | ||||||
| Gross margin | % | +53.46% | +57.87% | ||||||
| FCF/Sales | % | +12.75% | +13.95% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +104.94% | +170.68% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +980.70% | +1462.2% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.33 | 0.51 | ||||||
| Net Debt/EBITDA | x | 1.19 | -0.91 | ||||||
| EBIT/Net interest | x | 0.02 | 6.14 | ||||||
| Net debt/market cap | % | +6.72% | +0.61% | ||||||
| Net debt/Equity | x | 0.18 | 0.02 | ||||||
| Gross debt/equity | x | 1.19 | 0.62 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Eton Pharmaceuticals, Inc. (ETON)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free